In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4521-4524

  Clouse, Frances L ^a   Hovde, Laurie B ^a   Rotschafer, John C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; METICILLIN; TELAVANCIN; VANCOMYCIN;

ARTICLE; CONTROLLED STUDY; DIALYSATE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SIMULATION; STAPHYLOCOCCUS AUREUS; STATISTICAL SIGNIFICANCE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CEFAZOLIN; DIALYSIS SOLUTIONS; METHICILLIN; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PERITONEAL DIALYSIS; STAPHYLOCOCCUS AUREUS; TIME FACTORS; VANCOMYCIN;

EID: 36749083961     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00435-07     Document Type: Article

References (11)

1. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. CLSI document M100-A16. Clinical and Laboratory Standards Institute, Wayne, PA.
2. Cozens, R. M., E. Tuomanen, W. Tosch, O. Zak, J. Suter, and A. Tomasz. 1986. Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat. Antimicrob. Agents Chemother. 29:797-802.
3. Hegde, S. S., N. Reyes, T. Wiens, N. Vanasse, R. Skinner, J. McCullough, K. Kaniga, J. Pace, R. Thomas, J. Shaw, G. Obedencio, and J. K. Judice. 2004. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob. Agents Chemother. 48:3043-3050.
4. Hermsen, E. D., L. B. Hovde, J. R. Hotchkiss, and J. C. Rotschafer. 2003. Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob. Agents Chemother. 47:3764-3767.
5. McDonald, W. A., J. Watts, and M. I. Bowmer. 1986. Factors affecting Staphylococcus epidermidis growth in peritoneal dialysis solutions. J. Clin. Microbiol. 24:104-107.
6. Morton, A. R., G. Evas, A. Shannon, and D. Zoutman. 1994. Growth of coagulase negative staphylococci in peritoneal dialysate fluid: effect of calcium concentration. ASAIO J. 40:M431-M434.
7. Piraino, B., G. Bailie, J. Bernardini, E. Boeschoten, A. Gupta, C. Holmes, E. Kuijper, P. Li, W. Lye, S. Mujais, D. Paterson, M. Fontan, A. Ramos, F. Schaefer, and L. Uttley. 2005. Peritoneal dialysis-related infections recommendations: 2005 update. Perit. Dial. Int. 25:107-131.
8. Selgas, R., M. J. Fernandez-Reyes, E. Bosque, M. A. Bajo, F. Borrego, C. Jimenez, G. Del Peso, and F. De Alvaro. 1994. Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am. J. Kidney Dis. 23:64-73.
9. Shaw, J. P., J. Seroogy, K. Kaniga, D. L. Higgins, M. Kitt, and S. Barriere. 2005. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49:195-201.
10. Tuomanen, E., R. Cozens, W. Tosch, O. Zak, and A. Tomasz. 1986. The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J. Gen. Microbiol. 132:1297-1304.
11. Zelenitsky, S., C. Franczuk, A. Fine, R. Ariane, and G. Harding. 2002. Antibiotic tolerance of peritoneal bacterial isolates in dialysis fluids. J. Antimicrob. Chemother. 49:863-866.